Sign In
Buy PBM
$3.17
-0.190 (-5.65%)
At Close: Jul 31, 2026
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
08:37am, Tuesday, 17'th Dec 2024
Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN), h
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
07:30am, Tuesday, 17'th Dec 2024
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin Extract Vancouver, British Columbia--(Newsfile Corp.
CVS's Sell-Off May Be Overblown
09:30am, Sunday, 15'th Dec 2024
CVS plunged to $49, trading at a forward P/E of 8-9x, well below its 16x historical average. PBM segment contributes 46% of CVS income; fears of reform impact led to significant market overreaction. A
CVS Health Hits 11-Year Low; PBM Legislation Could Slash Earnings By 50%, Says Analyst
02:06pm, Thursday, 12'th Dec 2024
New legislation targeting pharmacy benefit managers (PBMs) could cut CVS Health earnings in half. CVS stock fell, along with UnitedHealth and Cigna.
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
07:30am, Tuesday, 10'th Dec 2024
Psyence Biomed obtains exclusive worldwide supply rights to Optimi's GMP-certified, nature-derived psilocybin for its drug development and commercialization initiatives in Palliative Care Psyence Biom
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
11:06am, Friday, 06'th Dec 2024
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-e
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
07:30am, Tuesday, 03'rd Dec 2024
Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
04:05pm, Tuesday, 19'th Nov 2024
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share conso
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at th
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
09:30am, Thursday, 31'st Oct 2024
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder, as previously announced PsyLabs to exclusive
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
10:43am, Monday, 14'th Oct 2024
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap A
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
04:05pm, Friday, 04'th Oct 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its pre
